Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Two of the distinguished in the latest edition of the Fronteras del Conocimiento FBBVA, endocrinologist Daniel J. Drucker and ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its ...

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...

Orfoglipron was associated with improved glycemic control and weight reduction among patients with early-stage type 2 diabetes.

LAGUNA NIGUEL, CA AND DUBLIN, CA / ACCESS Newswire / June 30, 2025 / Last Mile Solutions (LMS), a high-performance parcel ...